2022 edition of HealthTech Innovation Days: replay of “Translational microbiome medicine to treat serious oncology and infectious diseases”. During one…
Categorie
Media
Interview of Hervé Affagard, CEO and co-founder of MaaT Pharma, for Lyon Décideurs – Bourses & Valeurs during the Lyon…
October 18, 2022
La Bourse et la Vie interviewed Hervé Affagard, CEO and co-founder of MaaT Pharma, during the Investor Access Event: overview…
October 13, 2022
Interview of Hervé Affagard published in the July-August 2022 edition of MedNous, a business-science publication from Evernow Publishing Ltd. [image_with_animation…
July 22, 2022
Dive into the micobiome revolution with Dr. Joël Doré, INRAE Research Director, Scientific Director of Métagénopolis, Scientific advisor at MaaT…
June 27, 2022
[image_with_animation image_url=”7926″ animation=”Fade In” hover_animation=”none” alignment=”” border_radius=”none” box_shadow=”none” image_loading=”default” max_width=”100%” max_width_mobile=”default” img_link=”https://www.lerevenu.com/bourse/bourse-trois-biotechs-surveiller-avec-attention”]
June 13, 2022
[image_with_animation image_url=”7458″ animation=”Fade In” hover_animation=”none” alignment=”” border_radius=”none” box_shadow=”none” image_loading=”default” max_width=”100%” max_width_mobile=”default” img_link=”https://www.boursorama.com/bourse/actualites/le-journal-des-biotechs-herve-affagard-maat-pharma-mohamed-kaabouni-portzamparc-222699d7c3061381abc8b35a5a812c69?symbol=1rPMAAT”]
April 11, 2022
[image_with_animation image_url=”7604″ animation=”Fade In” hover_animation=”none” alignment=”” border_radius=”none” box_shadow=”none” image_loading=”default” max_width=”100%” max_width_mobile=”default” img_link=”https://www.boursier.com/actions/actualites/interviews/herve-affagard-co-fondateur-et-directeur-general-de-maat-pharma-5566.html”]
April 8, 2022
[image_with_animation image_url=”7587″ animation=”Fade In” hover_animation=”none” alignment=”” border_radius=”none” box_shadow=”none” image_loading=”default” max_width=”100%” max_width_mobile=”default” img_link=”https://investir.lesechos.fr/actions/actualites/maat-pharma-lance-son-etude-clinique-de-phase-2a-dans-le-melanome-2011222.php”]
April 8, 2022
[image_with_animation image_url=”7581″ animation=”Fade In” hover_animation=”none” alignment=”” border_radius=”none” box_shadow=”none” image_loading=”default” max_width=”100%” max_width_mobile=”default” img_link=”https://www.usinenouvelle.com/article/microbiote-maat-pharma-signe-une-premiere-et-debute-sa-phase-iii.N1802252″]
March 30, 2022
We are a clinical-stage microbiome therapeutics company aiming to improve survival in cancer.
Ressources
Contact
Nous sommes une société au stade clinique, spécialisée dans les thérapies issues du microbiote dédiées aux patients atteints de cancer.
Contact
Nous sommes une société au stade clinique, spécialisée dans les thérapies issues du microbiote dédiées aux patients atteints de cancer.